This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Acamprosate Calcium
Description: Campral (acamprosate) is a structural analogue of the amino acid homotaurine and the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is hypothesized to stabilize the balance between glutamate and GABA neurotransmitter systems in the brain, possibly by blocking glutamatergic NMDA receptors, while gamma-aminobutyric acid (GABA) type A receptors are activated. Acamprosate has also been noted to act as an antagonist when the NMDA receptors are maximally stimulated but as an agonist when NMDA receptor stimulation is minimal.
Campral was developed by Merck Sante s.a.s., a subsidiary of Merck KGaA, and licensed to Forest Laboratories for the United States.
Forest and Actavis
In February 2014, Actavis and Forest announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share ($26.04 in cash and 0.3306 Actavis shares for each share of Forest common stock).
In July 2014, Actavis announced that it has completed the acquisition of Forest in a cash and equity transaction currently valued at approximately $28 billion.
Actavis and Allergan
In June 2015, Actavis announced that the company has adopted Allergan as its new global name and will begin trading under a new symbol (AGN). The company name change follows the acquisition of Allergan in March 2015 and the approval of the name change by Actavis shareholders in June 2015.
...See full deal structure in Biomedtracker
Partners: Allergan plc
Pink Sheet Chart: Campral FDA Reviewers
Pink Sheet Forest/Lipha Campral
Additional information available to subscribers only: